Arylsulfonamide-based matrix metalloprotease inhibitors

Details Arylsulfonamide-based matrix metalloprotease inhibitors Arylsulfonamide-based matrix metalloprotease inhibitors

C - Chemistry, Metallurgy

07

C

C07C 311/16 (2006.01) A61K 31/18 (2006.01) A61P 29/00 (2006.01) C07C 317/24 (2006.01) C07C 323/24 (2006.01) C07D 207/20 (2006.01) C07D 209/08 (2006.01) C07D 211/24 (2006.01) C07D 213/40 (2006.01) C07D 235/06 (2006.01) C07D 295/116 (2006.01) C07D 333/18 (2006.01)

Patent

CA 2719457

The present invention provides a compound of formula (I):said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP- 13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP- 13. Finally, the present invention also provides a pharmaceutical composition.

La présente invention concerne un composé de formule (I) : ledit composé étant un inhibiteur de MMP-2 et/ou de MMP-8 et/ou de MMP-9 et/ou de MMP-12 et/ou de MMP-13 et pouvant donc être employé pour le traitement dun trouble ou dune maladie caractérisé par une activité anormale de MMP-2 et/ou de MMP-8 et/ou de MMP-9 et/ou de MMP-12 et/ou de MMP-13. Par conséquent, le composé de formule (I) peut être utilisé pour le traitement de troubles ou de maladies médiés par MMP-2 et/ou MMP-8 et/ou MMP-9 et/ou MMP-12 et/ou MMP-13. Enfin, la présente invention concerne également une composition pharmaceutique.

Affiliated with

Also associated with

Rating

Arylsulfonamide-based matrix metalloprotease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Arylsulfonamide-based matrix metalloprotease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylsulfonamide-based matrix metalloprotease inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1343163